6-K 1 zk2125668.htm 6-K

SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
______________________
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
 
For the month of February 2021
 
Commission File Number: 001-36349

 MediWound Ltd.
(Translation of registrant’s name into English)
 
42 Hayarkon Street
Yavne, 8122745 Israel
 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F ☒          Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __
 
EXPLANATORY NOTE
 
On February 25, 2021, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

2
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MEDIWOUND LTD.
  
       
Date: February 25, 2021
By:
/s/ Boaz Gur-Lavie  
  Name: Boaz Gur-Lavie  
  Title:
 Chief Financial Officer  
3

EXHIBIT INDEX

The following exhibit is filed as part of this Form 6-K:

Exhibit
 Description

99.1

4